Literature DB >> 26085728

Anaphylactic Shock Secondary to Intravenous Iron Sucrose in Chronic Kidney Disease.

Vineet Behera1, Rajeev Chauhan2, Smriti Sinha2, Velu Nair3.   

Abstract

Intravenous (IV) iron is an essential component of therapy of anemia of chronic kidney disease (CKD). We present a rare case in which iron sucrose was infused to a patient of CKD and resulted in severe anaphylaxis and cardiac arrest minutes after starting the infusion. He was aggressively resuscitated with adrenaline and other measures following which he recovered. The use of parenteral iron is associated with several adverse drug reactions (ADR) which were seen with preparations like iron dextran but became rare with the use of newer safe preparations like iron sucrose or gluconate. The ADR can be mild or can have severe life threatening features like syncope, cardiac arrhythmias, seizures, bronchospasm and rarely cardio respiratory arrest like in our case. Iron sucrose is generally given as a IV infusion of 100-200 mg over 15-30 min and has a very low rate of ADR even with higher doses or bolus injections. But still necessary precautions and appropriate monitoring must be done in all patients. The patients who are allergic to iron sucrose may be treated with other safer preparations or by desensitisation techniques.

Entities:  

Keywords:  Allergic reaction; Anaphylactic shock; Chronic kidney disease; Intravenous iron; Iron sucrose

Year:  2014        PMID: 26085728      PMCID: PMC4465511          DOI: 10.1007/s12288-014-0475-0

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  10 in total

1.  Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.

Authors:  D B Van Wyck; G Cavallo; B S Spinowitz; R Adhikarla; S Gagnon; C Charytan; N Levin
Journal:  Am J Kidney Dis       Date:  2000-07       Impact factor: 8.860

2.  Intravenous iron sucrose: establishing a safe dose.

Authors:  G Chandler; J Harchowal; I C Macdougall
Journal:  Am J Kidney Dis       Date:  2001-11       Impact factor: 8.860

3.  Suspected iron dextran-related adverse drug events in hemodialysis patients.

Authors:  R Fletes; J M Lazarus; J Gage; G M Chertow
Journal:  Am J Kidney Dis       Date:  2001-04       Impact factor: 8.860

4.  Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections.

Authors:  Iain C Macdougall; Alison Roche
Journal:  Am J Kidney Dis       Date:  2005-08       Impact factor: 8.860

5.  Structure, chemistry, and pharmacokinetics of intravenous iron agents.

Authors:  Bo G Danielson
Journal:  J Am Soc Nephrol       Date:  2004-12       Impact factor: 10.121

6.  II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults.

Authors: 
Journal:  Am J Kidney Dis       Date:  2006-05       Impact factor: 8.860

7.  [Parenteral iron therapy: problems and possible solutions].

Authors:  R Hoigné; C Breymann; U P Künzi; F Brunner
Journal:  Schweiz Med Wochenschr       Date:  1998-04-04

8.  Anemia of inflammation: the cytokine-hepcidin link.

Authors:  Nancy C Andrews
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

9.  Anaphylaxis to oral iron salts. desensitization protocol for tolerance induction.

Authors:  M de Barrio; V Fuentes; P Tornero; I Sánchez; J Zubeldia; T Herrero
Journal:  J Investig Allergol Clin Immunol       Date:  2008       Impact factor: 4.333

10.  Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis.

Authors:  H S Novey; M Pahl; I Haydik; N D Vaziri
Journal:  Ann Allergy       Date:  1994-03
  10 in total
  1 in total

1.  Impact of European medicines agency recommendations for hypersensitivity reactions on intravenous iron prescription in haemodialysis centres of the Lombardy region.

Authors:  Rodolfo F Rivera; Davide Guido; Lucia Del Vecchio; Enzo Corghi; Marco D'Amico; Corrado Camerini; Donatella Spotti; Andrea Galassi; Claudio Pozzi; Giovanni Cancarini; Giuseppe Pontoriero; Francesco Locatelli
Journal:  J Nephrol       Date:  2015-12-29       Impact factor: 3.902

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.